
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air is currently in a transitional period as it undergoes a leadership change, with the appointment of Robert Goodman as CEO. This transition signals a focus on commercialization and revenue growth, as evidenced by the company's reported fiscal 3Q26 revenue of $2.2M. Additionally, the company's recent interim data for its Beyond Cancer segment showed encouraging results, with potential for the NeuroNOS asset to generate value in the future.
Bears say
Beyond Air is facing multiple risks, including financial and capital risks, commercialization risks, and clinical development risks. The company's dependence on third-party partnerships and its reliance on its intellectual property also pose potential challenges. While it has achieved approval for its primary commercial product, the LungFit PH system, its optional asset, the NeuroNOS platform, may not generate significant revenue in the near future. Management should focus on expanding hospital adoption and pursuing other pulmonary indications to mitigate these risks.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares